No stim will ever be MR compatible. They will always be conditional. The number one condition is that you must turn it off prior to a scan. The second is that you can only have a MRI in 1.5 or 3T magnet.
Nuvectra?
- Thread starter anonymous
- Start date
-
- Tags
- None
No stim will ever be MR compatible. They will always be conditional. The number one condition is that you must turn it off prior to a scan. The second is that you can only have a MRI in 1.5 or 3T magnet.
This is all you can think about and max hardcore went to jail for obscenity
They'll always be conditional so long as they have metal in it but those conditions could be so general or encompassing of current technology that the device might be, for practical purposes, safe to scan at all conditions The reason why you're limited to 1.5 or 3T magnets is because that's what they manufacturer tests because that's almost all of your commercially-available scanners. If your material is sufficiently non-magnetic you could scan at a higher field strength. Depends on how paramagnetic the material is.
You won't necessarily have to turn off future devices in 1.5 or 3T scanners. If you had a lead that you could shield sufficiently from the RF, or have circuitry in the IPG to deal with the induced current, or a device small enough that it didn't generate a significant amount of current and therefore heat, you could have a device that you left on during a scan. Since spinal cord stimulators don't make use of sensing, there's nothing stopping a manufacturer from making a device that's MRI conditionally safe while on. It's just a lot harder, the testing is more expensive, and the patient population that benefits is relatively small. So they don't. There are some pacemakers, for example, that can be on for an MRI scan. You just reprogram them to an asynchronous mode (VOO/DOO) at a fixed rate and high output for pacing-dependent patients. It's all about the risk benefit.
MRI compatibility is a nice feature, but which stimulator gives patients the best pain relief?
asks the rep without an MR conditional device in the bag.
Weak answer. Let me try: It's Nevro.
Nevro has head and extremity. Full body not far off. Good luck to you.
Funny, Drees says maybe Q1 '18 and you approval by end of summer???
Well, when they get MRI, everything is going to change overnight, cause you know, MRI is what it's all about.
Guess you were right.
https://globenewswire.com/news-rele...DA-for-Algovita-MRI-Conditional-Approval.html
6/21/2017 + 180 = 12/18/2017
So we will can expect Algovita MRI approval before Q1 of next year? I'll be sure to mark my calendar for their imminent domination of the SCS space.
Any updates on Nuvectra? Are there any reps on here, on plan, ahead, behind?
Not even close to plan, just getting close to being put on one if I do not get more interested implanters
((((report earnings soon so us competitors will know what the story is over there
Just listened to conference call-these guys are executing well and have a real product
LOL! You are joking, right? They only have 35 mil left in the bank....about a year. 5.5 million in sales is terrible even if they say 180ish growth from last year. 1/4 of Nuvectra's sales are not from Stim and they are operating from a loss more than double their sales. You do the math.
They have 50 reps and did ~5million last qtr. after 2 yrs on the market. Not good. Mgmt team has decent reputation but the product hasn't turned enough heads. No clinical data, not High frequency = price driven sale.
Biggest warning sign is they have already begun working with US distributors. There are many good reasons why all the SCS players avoided that. Nuvectra is desperate though.
Their existence depends on performance in the urinary incontinence market. Hard to see them being profitable anytime soon, and at their low revenue footprint they are definitely in trouble.
Biggest warning sign is they have already begun working with US distributors. There are many good reasons why all the SCS players avoided that. Nuvectra is desperate though.
Their existence depends on performance in the urinary incontinence market. Hard to see them being profitable anytime soon, and at their low revenue footprint they are definitely in trouble.